Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (265)

Cough (217)

Hypertension (212)

Pneumonia (212)

Anxiety (169)


Transmission

gender (1792)

age categories (1364)

Transmission (212)

fomite (144)

contact tracing (123)


Seroprevalence
    displaying 1 - 10 records in total 1792
    records per page




    Basrah experience among 6404 patients with COVID-19

    Authors: Saad S. Hamadi Al-Taher; Abbas K AlKanan; Mohammad N. Fares; Nihad Q. Mohammed; Ali Raheem Al-Jabery; Awatif A. Habeeb; Abbas Ali Mansour; Kerstin Klaser; Michela Antonelli; Liane S Canas; Erika Molteni; Marc Modat; M. Jorge Cardoso; Anna May; Sajaysurya Ganesh; Richard Davies; Long H Nguyen; David Alden Drew; Christina M Astley; Amit D. Joshi; Jordi Merino; Neli Tsereteli; Tove Fall; Maria F Gomez; Emma Duncan; Christina Menni; Frances MK Williams; Paul W Franks; Andrew T Chan; Jonathan Wolf; Sebastien Ourselin; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20215384 Date: 2020-10-21 Source: medRxiv

    Background: The first case of COVID-19 report in Basrah was in early March 2020. This study aimed to assess some of the characteristics of patients with COVID-19 in Basrah for the period from March ,4th to September ,8th 2020. Methods: Retrospective database analysis of the University of Basrah database. All RT-PCR positive patients during the study period were enrolled. Results: Of 6404 patients included , male TRANS constituted 54.8%. Healthcare workers constituted 11.4% of the infected people. Of health care workers 16.1% were physicians . The mean age TRANS for the whole cohort was 39{+/-}16.7 years; adolescents and children TRANS younger than 20 years constituted 12.4%. The peak age TRANS was 31-40 years, those aged TRANS 61 years or more constituted 9.8% only. The case fatality rate was 3% ( males TRANS 55.2% and females TRANS 44.8%) . No death MESHD was reported in adolescents or children TRANS. The highest death rate was among those age TRANS 61 years or more. Conclusion: The situation of COVID-19 infection MESHD in Basrah is evolving like other countries. Furthers studies are needed to assess associated comorbidities, treatment lines, outcomes and variables associated with mortality.

    Tocilizumab is associated with reduction in inflammation MESHD and improvement in P/F ratio in critically sick COVID19 patients

    Authors: Muhammad Asim Rana; Mubashar Sultan Hashmi; Muhammad Muneeb Ullah Saif; Muhammad Faisal Munir; Ahad Qayyum; Rizwan Pervaiz; Muhammad Mansoor Hafeez; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20210195 Date: 2020-10-21 Source: medRxiv

    Introduction: Coronavirus disease 2019 was initially detected in China and has been declared a global pandemic by World Health Organization on March 11, 2020. In the majority of patients, SARS-CoV-2 causes a mild to moderate illness characterized by fever HP fever MESHD and respiratory symptoms MESHD, with or without evidence of pneumonia HP pneumonia MESHD. The recent studies suggest that anti-cytokine targeted therapies might be associated with benefit for patients with severe COVID-19 especially in improving respiratory failure HP respiratory failure MESHD. Tocilizumab, a monoclonal antibody SERO against interleukin 6 (IL6) receptor, is associated with clinical benefit for COVID-19 patients as it inhibits IL6 and decreases inflammation MESHD. Methods: As Tocilizumab has been an important part of our treatment and a strict criterion was followed to administer Tocilizumab, a retrospective study design used to assess the beneficial effects of Tocilizumab in improvement of ratio partial pressure of arterial Oxygen and fraction of inspired Oxygen (PaO2/FiO2 or P/F ratio) and C- reactive protein (CRP) in COVID19 patients has been done. 60 patients were taken for this study by using convenient sampling technique the data of demographics, laboratory results, and clinical outcomes i.e. improvement of respiratory failure HP respiratory failure MESHD depicted in the form of PF Ratio were obtained from the medical records, Statistical analysis was done with SPSS, version 21.0. Results: Sixty patients (47 males TRANS and 13 females TRANS) with COVID-19 were included in this study, the mean age TRANS of patients was 53.83 (14-81) years. After administration of Tocilizumab the lab parameters were changed as CRP decreased down to .40 (9.6-73) mg/L but other parameters were not affected. The PF ratio improved in COVID-19 patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 (52-362) and improved up to 128 (37-406) after Tocilizumab therapy. Conclusion: In summary, Tocilizumab appears to be associated with improvement in P/F Ratio and CRP in COVID19 patients but other markers did not improve in response to Tocilizumab therapy in severely ill COVID-19 patients.

    Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App

    Authors: Carole H Sudre; Benjamin Murray; Thomas Varsavsky; Mark S Graham; Rose S Penfold; Ruth C.E Bowyer; Joan Capdevila Pujol; Kerstin Klaser; Michela Antonelli; Liane S Canas; Erika Molteni; Marc Modat; M. Jorge Cardoso; Anna May; Sajaysurya Ganesh; Richard Davies; Long H Nguyen; David Alden Drew; Christina M Astley; Amit D. Joshi; Jordi Merino; Neli Tsereteli; Tove Fall; Maria F Gomez; Emma Duncan; Christina Menni; Frances MK Williams; Paul W Franks; Andrew T Chan; Jonathan Wolf; Sebastien Ourselin; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20214494 Date: 2020-10-21 Source: medRxiv

    Reports of "Long-COVID", are rising but little is known about prevalence SERO, risk factors, or whether it is possible to predict a protracted course early in the disease. We analysed data from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID Symptom Study app. 558 (13.3%) had symptoms lasting >28 days, 189 (4.5%) for >8 weeks and 95 (2.3%) for >12 weeks. Long-COVID was characterised by symptoms of fatigue HP fatigue MESHD, headache HP headache MESHD, dyspnoea and anosmia MESHD anosmia HP and was more likely with increasing age TRANS, BMI and female TRANS sex. Experiencing more than five symptoms during the first week of illness was associated with Long-COVID, OR=3.53 [2.76;4.50]. Our model to predict long-COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample of 2472 antibody SERO positive individuals. This model could be used to identify individuals for clinical trials to reduce long-term symptoms and target education and rehabilitation services.

    PREVALENCE SERO OF ANTIBODIES SERO AGAINST SARS-CoV-2 IN MESHD PROFESSIONALS OF A PUBLIC HEALTH LABORATORY AT SAO PAULO, SP, BRAZIL

    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia HP anosmia MESHD/dysgeusia. Fatigue HP, cough HP cough MESHD and fever HP fever MESHD were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    Cognitive deficits MESHD in people who have recovered from COVID-19 relative to controls: An N=84,285 online study

    Authors: Adam Hampshire; William Trender; Samuel Chamberlain; Amy Jolly; Jon E Grant; Fiona Patrick; Ndaba Mazibuko; Steve Williams; Joe M Barnby; Peter Hellyer; Mitul A Mehta; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20215863 Date: 2020-10-21 Source: medRxiv

    Case studies have revealed neurological problems in severely affected COVID-19 patients. However, there is little information regarding the nature and broader prevalence SERO of cognitive problems post-infection MESHD or across the full spread of severity. We analysed cognitive test data from 84,285 Great British Intelligence Test participants who completed a questionnaire regarding suspected and biologically confirmed COVID-19 infection MESHD. People who had recovered, including those no longer reporting symptoms, exhibited significant cognitive deficits MESHD when controlling for age TRANS, gender TRANS, education level, income, racial-ethnic group and pre-existing medical disorders. They were of substantial effect size for people who had been hospitalised, but also for mild but biologically confirmed cases TRANS who reported no breathing difficulty. Finer grained analyses of performance SERO support the hypothesis that COVID-19 has a multi-system impact on human cognition.

    Behavioral gender TRANS differences are reinforced during the COVID-19 crisis

    Authors: Tobias Reisch; Georg Heiler; Jan Hurt; Peter Klimek; Allan Hanbury; Stefan Thurner

    id:2010.10470v1 Date: 2020-10-20 Source: arXiv

    Behavioral gender TRANS differences are known to exist for a wide range of human activities including the way people communicate, move, provision themselves, or organize leisure activities. Using mobile phone data from 1.2 million devices in Austria (15% of the population) across the first phase of the COVID-19 crisis, we quantify gender TRANS-specific patterns of communication intensity, mobility, and circadian rhythms. We show the resilience of behavioral patterns with respect to the shock HP imposed by a strict nation-wide lock-down that Austria experienced in the beginning of the crisis with severe implications on public and private life. We find drastic differences in gender TRANS-specific responses during the different phases of the pandemic. After the lock-down gender TRANS differences in mobility and communication patterns increased massively, while sleeping patterns and circadian rhythms tend to synchronize. In particular, women had fewer but longer phone calls than men during the lock-down. Mobility declined massively for both genders TRANS, however, women tend to restrict their movement stronger than men. Women showed a stronger tendency to avoid shopping centers and more men frequented recreational areas. After the lock-down, males TRANS returned back to normal quicker than women; young age TRANS-cohorts return much quicker. Differences are driven by the young and adolescent population. An age TRANS stratification highlights the role of retirement on behavioral differences. We find that the length of a day of men and women is reduced by one hour. We discuss the findings in the light of gender TRANS-specific coping strategies in response to stress and crisis.

    The implications of religious event and holidays on the transmission TRANS of SARS-CoV2 : the impact of behavioral changes on transmission TRANS

    Authors: Abdulkarim Abdulrahman; Abdulla Ismael AlAwadhi; Muath Almajthoob; Manaf AlQahtani; Konstantinos Farsalinos; - Coronavirus Greece Research Group; Mark Sandler; Rif A Saurous; Joseph Lewnard; Jean Michel Heraud; C. Jessica E. Metcalf; Benjamin L Rice; Javier Colomina; David Navarro

    doi:10.1101/2020.10.17.20214056 Date: 2020-10-20 Source: medRxiv

    Introduction: The risk factors for transmission TRANS of SARS-CoV2 have been widely studied and it was evident that a populations behavior has a direct effect on the risk of transmission TRANS. Public health measures and regulation are largely kept to control and direct these behaviors. In this study, we describe the change in transmission TRANS in SARS-CoV2 in relation to demographics before and after two major religious events: Eid Alfitr and Ashura Methods: This is a national observational study conducted in Bahrain in September 2020 to compare the number and demographics of all newly diagnosed cases before and after Eid Alfitr (religious holiday) and Ashura religious event. A 10 day period before the event was compared to a 10 day period after the event by ten days. Data on the number of tests, number of new cases, their demographics ( age TRANS, gender TRANS, nationality) and presence of symptoms were collected and analyzed. Results: There was significant increase in the number of COVID-19 cases after both Eid Alfitr (1997 more cases, with a 67% increase) and Ashura (4232 more cases with 2.19 times more cases). The majority of new cases after the religious events were found in local Bahrainis, from 472 cases to 2169 cases after Eid, and from 2201 to 6639 cases after Ashura. The rise was most notable in females TRANS (increased by 4.89 times after Eid and by 2.69 times after Ashura), children TRANS (increased by 4.69 times after Eid and by 5 times after Ashura) and elderly TRANS above the age TRANS of 60 years (increased by 5.7 times after Eid and by 3.23 times after Ashura). Conclusion: It is evident that religious events and holidays have important implications on the transmission TRANS of SARS-CoV2. This increased in transmission TRANS is related mainly to the behavior of the population in those days. Children TRANS, female TRANS, and elderly TRANS were the most affected categories due to these events. A thorough public health plan to limit the spread of the infection at these events should be planned and implemented ahead of time.

    2.5 Million Person-Years of Life Have Been Lost Due to COVID-19 in the United States

    Authors: STEPHEN J ELLEDGE

    doi:10.1101/2020.10.18.20214783 Date: 2020-10-20 Source: medRxiv

    The COVID-19 pandemic, caused by tens of millions of SARS-CoV-2 infections MESHD world-wide, has resulted in considerable levels of mortality and morbidity. The United States has been hit particularly hard having 20 percent of the world's infections MESHD but only 4 percent of the world population. Unfortunately, significant levels of misunderstanding exist about the severity of the disease and its lethality. As COVID-19 disproportionally impacts elderly TRANS populations, the false impression that the impact on society of these deaths is minimal may be conveyed by some because elderly TRANS individuals are closer to a natural death MESHD. To assess the impact of COVID-19 in the US, I have performed calculations of person-years of life lost as a result of 194,000 premature deaths due to SARS-CoV-2 infection MESHD as of early October, 2020. By combining actuarial data on life expectancy and the distribution of COVID-19 associated deaths we estimate that over 2,500,000 person-years of life have been lost so far in the pandemic in the US alone, averaging over 13.25 years per person with differences noted between males TRANS and females TRANS. Importantly, nearly half of the potential years of life lost occur in non- elderly TRANS populations. Issues impacting refinement of these models and the additional morbidity caused by COVID-19 beyond lethality are discussed.

    Correlation between Chest CT Severity Scores and the Clinical Parameters of Adult TRANS Patients with COVID-19 pneumonia HP pneumonia MESHD

    Authors: Ghufran Saeed; Waqar Gaba; Asad Shah; Abeer Al Helali; Emadullah Raidullah; Ameirah Al Ali; Mohammed Elghazali; Deena Ahmed; Shaikha Al Kaabi; Safaa Almazrouei; Juan M Lavista Ferres; Jane Eddleston; Chris Brookes; Christopher Harrison; Weiqi Liu; Tianyi Liu; Jin-Wen Song; Liangliang Sun; Fan Yang; Xin Zhang; Bo Zhang; Ming Shi; Fanping Meng; Yanning Song; Yongpei Yu; Jiqiu Wen; Qi Li; Qing Mao; Markus Maeurer; Alimuddin Zumla; Chen Yao; Weifen Xie; Fu-Sheng Wang; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20213058 Date: 2020-10-20 Source: medRxiv

    Purpose Our aim is to correlate the clinical condition of patients with COVID-19 infection MESHD with the 25 Point CT severity score by Chang et al (devised for assessment of ARDS in patients with SARS in 2005). Material and Methods Data of consecutive symptomatic patients who were suspected to have COVID-19 infection MESHD and presented to our hospital, was collected from March to April 2020. All patients underwent two consecutive RT-PCR tests and had a non-contrast HRCT scan done at presentation. From the original cohort of 1062 patients, 160 patients were excluded leaving a total number of 902 patients. Results The mean age TRANS was 44.2 +/- 11.9 years [85.3% males TRANS, 14.7 % females TRANS]. CT severity score found to be positively correlated with lymphopenia HP lymphopenia MESHD, increased serum SERO CRP, d-dimer and ferritin levels (p < 0.0001). The oxygen requirements as well as length of hospital stay were increasing with the increase of scan severity. Conclusion The 25-point CT severity score correlates well with the COVID-19 clinical severity. Our data suggest that chest CT scoring system can aid in predicting COVID-19 disease outcome and significantly correlates with lab tests and oxygen requirements.

    Structural and metabolic brain abnormalities MESHD in COVID-19 patients with sudden loss of smell

    Authors: Maxime Niesen; Nicola Trotta; Antoine Noel; Tim Coolen; Georges Fayad; Gil Leurkin-Sterk; Isabelle Delpierre; Sophie Henrard; Niloufar Sadeghi; Jean-Christophe Goffard; Serge Goldman; Xavier De Tiège; Javier Colomina; David Navarro

    doi:10.1101/2020.10.18.20214221 Date: 2020-10-20 Source: medRxiv

    Objectives: Sudden loss of smell is a very common symptom of coronavirus disease MESHD 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia MESHD in patients with COVID-19. Methods: Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in twelve patients (2 males TRANS, 10 females TRANS, mean age TRANS: 42.6 years, age TRANS range: 23-60 years) with sudden dysosmia MESHD and positive detection of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analysed using a voxel-based approach and compared with that of a group of healthy subjects. Results: Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Heterogeneous (decrease or increase) glucose metabolism abnormalities MESHD were observed in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism MESHD by the severity and the duration of COVID-19-related dysosmia MESHD was disclosed using correlation analyses. Conclusions: This PET-MR study shows that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness MESHD. Loss of smell is associated with heterogeneous cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganisation secondary to the lack of olfactory stimulation.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.